China-based Proviva Therapeutics has completed a Series A+ funding round of over USD 30 million, led by OrbiMed. The proceeds will accelerate global clinical development of its lead candidate, PTX-912, and advance multiple pre-clinical assets. Proviva is a clinical-stage biotech focused on next-generation immuno-oncology therapies, leveraging its proprietary platforms — CROSSOVER (cytokine prodrug technology) and MUSICA (multifunctional effector cell activation) — to address key limitations of conventional therapies, such as systemic toxicity and low precision in immune cell activation.

PTX-912, a first-in-class PD-1/IL-2 prodrug fusion protein, is currently in Phase I dose escalation, demonstrating promising safety and an early confirmed partial response in non-small cell lung cancer (NSCLC). The molecule’s design reduces systemic toxicity while enhancing tumour-targeted IL-2 delivery and immune activation. Founder and CEO Harry Zhou emphasised plans to expand clinical development and explore partnerships, aiming to deliver transformative treatments globally.

PharmCube's MedAlpha® database shows that this is the fifth investment Proviva has received. Click here to request a free trial for MedAlpha®.